Halozyme Therapeutics, Inc.
HALO
Positions held
Your positionsHALO isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Halozyme Therapeutics is well-positioned in the biotechnology sector with a strong focus on innovative therapies, which enhances its competitive edge in a rapidly evolving industry.
- Revenue increased by 28% compared to the prior quarter, reaching $481 million.
- Gross margin improved to 83.5%, up from 79% in the previous quarter.
- The company's high debt-to-equity ratio of 1517.69 raises concerns about financial stability and leverage risk.
- Net income for the fourth quarter of 2025 was negative at -$141.591 million.
- The trailing P/E ratio stands at 32.08, indicating potential overvaluation compared to industry peers.
Fundamentals
| Market cap | $12.47B | Enterprise value | $14.41B | Trailing P/E | 32.12 | Forward P/E | 10.33 |
| PEG | — | Price / book | 87.24 | Beta | 0.88 | Dividend yield | 0.00% |
| Revenue growth | 47.7% | Earnings growth | 42.9% | Gross margin | 76.3% | Operating margin | 59.8% |
| Profit margin | 24.9% | ROE | 1.7% | ROA | 25.5% | Debt / equity | 15.18 |
| Current ratio | 2.71 | Free cash flow | $337.31M | Analyst recommendation | buy | Mean target | $102.11 |
| 52w high | $116.85 | 52w low | $61.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $481M | $377M | $452M | $354M | $326M |
| Op margin | 59.8% | 49.0% | 53.3% | 61.5% | 62.2% |
| Net income | $230M | $150M | -$142M | $175M | $165M |
| Gross margin | 83.5% | 79.0% | 82.6% | 84.4% | 85.8% |
| Gross profit | $402M | $297M | $373M | $299M | $279M |
| Operating income | $288M | $185M | $241M | $218M | $202M |
- Revenue +28% vs prior quarter ($481M vs $377M).
- Gross margin 83.5% (was 79% prior quarter).
- Operating margin expanded to 59.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.0B | $829M | $660M | — |
| Op margin | 57.5% | 54.3% | 40.7% | 40.5% | — |
| Net income | $317M | $444M | $282M | $202M | — |
| Gross margin | 83.6% | 84.3% | 76.8% | 78.9% | — |
| Gross profit | $1.2B | $856M | $637M | $521M | — |
| Operating income | $803M | $551M | $338M | $268M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Halozyme Therapeutics Insider Sold Shares Worth $6,610,501, According to a Recent SEC Filing
2026-10-08 · HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
2026-10-08 · Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value?
2026-10-07 · Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?
2026-10-07 · Sector Update: Healthcare Stocks Rise Late Afternoon
2026-10-07 · Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock.
2026-10-07 · Sector Update: Healthcare Stocks Rise in Afternoon Trading
2026-10-07 · Sector Update: Healthcare
2026-10-07 · Halozyme stock rises after winning injunction against Merck
2026-10-07 · Update: Halozyme Wins Injunction Against Merck's Keytruda SC in Multiple EU Markets
2026-10-07 · HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
2026-10-07 · Halozyme Wins Injunction Against Merck's Keytruda SC in Multiple EU Markets
Price (daily)
Full chart · RSI · MACD · patterns